Introduction & Objective: Certain glucagon-like peptide receptor agonists (GLP-1RA) are indicated in different formulations for the treatment of obesity and diabetes. The study objective was to describe real-world demographics, clinical characteristics, and treatment patterns among GLP-1RA users by indication (type 2 diabetes mellitus [T2DM] and chronic weight management [CWM]).
Methods: This was a descriptive retrospective cohort study using Optum’s Market Clarity database, which has linked EHR and claims data. Patients with ≥1 prescription for GLP-1RAs of interest (semaglutide and liraglutide) between 2010 and 2020 were included in the cohort if they had at least 90 days of enrollment/clinical activity prior to index and 365 days of follow-up. Analyses were stratified by GLP-1RA indication.
Results: There were 517,876 GLP-1RA users identified, 473,355 for T2DM and 44,521 for CWM. BMI was similar, while CWM patients were younger, more likely to be female, and have lower prevalence of certain comorbidities compared to T2DM patients (Table). GLP-1RA duration differed by indication for use ≥6 months (T2DM: 46%, CWM: 28%) and > one year (T2DM: 29%, CWM: 13%).
Conclusion: Real-world patients using GLP-1RAs for T2DM and CWM have comparable BMI despite differences in age, sex, and clinical characteristics. Duration of GLP-1RA use is short in clinical practice.
M.S. Girguis: Employee; Amgen Inc. M. Lillie: Employee; Amgen Inc. E. Bodner: None. C.K. Kasrai: None. J.R. Spencer: None. A. Cancino Nunez: Employee; Novo Nordisk. Stock/Shareholder; Novo Nordisk. Employee; Amgen Inc. Stock/Shareholder; Amgen Inc. J. O'Kelly: Employee; Amgen Inc. Stock/Shareholder; Amgen Inc.
